Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Roca Alonso, L ^a   Castellano, L ^a   Mills, A ^b   Dabrowska, A F ^a   Sikkel, M B ^b   Pellegrino, L ^a   Jacob, J ^a   Frampton, A E ^a   Krell, J ^a   Coombes, R C ^a   Harding, S E ^b   Lyon, A R ^b,c   Stebbing, J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; DOXORUBICIN; MICRORNA; MICRORNA 30; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR GATA 6; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; BETA ADRENERGIC RECEPTOR; GATA6 PROTEIN, HUMAN; GATA6 PROTEIN, RAT; MIRN30 MICRORNA, RAT;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; IN VIVO STUDY; INHIBITION KINETICS; LONG TERM EXPOSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE CELL; DRUG EFFECTS; GENETICS; HEART INFARCTION; HUMAN; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; DOWN-REGULATION; DOXORUBICIN; GATA6 TRANSCRIPTION FACTOR; HUMANS; MALE; MICRORNAS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 84957309633     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.89     Document Type: Article

References (70)

1. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992; 19: 670-686.
2. Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-741.
3. Hjalmarson A, Waagstein F. The role of [beta]-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994; 47: 31-40.
4. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261: 3060-3067.
5. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T et al. p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS ONE 2011; 6: e18005.
6. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229.
7. Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, Liu LF et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18: 1639-1642.
8. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 1999; 96: 7059-7064.
9. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of β-adrenergic signaling in heart failure? Circ Res 93: 896-906.
10. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A et al. Increased messenger RNA level of the inhibitory G protein alpha subunit Gi alpha-2 in human end-stage heart failure. Circ Res 1992; 70: 688-696.
11. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL et al. Increase of the 40,000- mol wt pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest 1988; 82: 189-197.
12. Eichhorn EJ. The paradox of β-adrenergic blockade for the management of congestive heart failure. Am J Med 1992; 92: 527-538.
13. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1036.
14. Bartel D. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
15. Marco A, Ninova M, Ronshaugen M, Griffiths-Jones S. Clusters of microRNAs emerge by new hairpins in existing transcripts. Nucleic Acids Res 2013; 41: 7745-7752.
16. Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
17. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
18. Chen J-F, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci USA 2008; 105: 2111-2116.
19. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008; 118: 1567-1576.
20. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129: 303-317.
21. van Rooij E. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103: 18255-18260.
22. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW et al. MicroRNAs in the Human Heart. Circulation 2007; 116: 258-267.
23. van Rooij E, Sutherland L, Qi X, Richardson J, Hill J, Olson E. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579.
24. Dong D-L, Chen C, Huo R, Wang N, Li Z, Tu Y-J et al. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy. Hypertension 2010; 55: 946-952.
25. Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 2010; 87: 656-664.
26. Vacchi-Suzzi C, Bauer Y, Berridge BR, Bongiovanni S, Gerrish K, Hamadeh HK et al. Perturbation of microRNAs in Rat Heart during Chronic Doxorubicin Treatment. PLoS One 2012; 7: e40395.
27. Siveski-Iliskovic N, Kaul N, Singal P. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89: 2829-2835.
28. Lyon AR, MacLeod KT, Zhang Y, Garcia E, Kanda GK, Lab MJ et al. Loss of T-tubules and other changes to surface topography in ventricular myocytes from failing human and rat heart. Proc Natl Acad Sci 2009; 106: 6854-6859.
29. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105: 13027-13032.
30. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-984.
31. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I et al. miR-133 and miR-30 regulate connective tissue growth factor. Circ Res 104: 170-178.
32. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13: 613-618.
33. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 2010; 122: S124-S131.
34. Shieh JTC, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS One 2011; 6: e19481.
35. Wang G-K, Zhu J-Q, Zhang J-T, Li Q, Li Y, He J et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666.
36. Lewis B, Burge C, Bartel D. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
37. Chen Y, Lewis W, Diwan A, EH-Y Cheng, Matkovich SJ, Dorn GW. Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci USA 2010; 107: 9035-9042.
38. Ding W-X, Ni H-M, Li M, Liao Y, Chen X, Stolz DB et al. Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and parkin-ubiquitinp62- mediated mitochondrial priming. J Biol Chem 2010; 285: 27879-27890.
39. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW. Nix-Mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117: 396-404.
40. Yussman MG, Toyokawa T, Odley A, Lynch RA, Wu G, Colbert MC et al. Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy. Nat Med 2002; 8: 725-730.
41. L'Ecuyer T, Horenstein MS, Thomas R, Vander Heide R. Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies. Mol Genetics Metab 2001; 74: 370-379.
42. Hescheler J, Meyer R, Plant S, Krautwurst D, Rosenthal W, Schultz G. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 1991; 69: 1476-1486.
43. Hamdani N, Velden J. Lack of specificity of antibodies directed against human betaadrenergic receptors. Naunyn Schmiedeberg Arch Pharmacol 2009; 379: 403-407.
44. Pradidarcheep W, Stallen J, Labruyère W, Dabhoiwala N, Michel M, Lamers W. Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedeberg Arch Pharmacol 2009; 379: 397-402.
45. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Meth 2007; 4: 721-726.
46. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax Ratio. Cancer Res 2002; 62: 4592-4598.
47. Oltval ZnN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993; 74: 609-619.
48. Lv X, Yu X, Wang Y, Wang F, Li H, Wang Y et al. Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression. PLoS One 2012; 7: e47351.
49. Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L et al. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol 2009; 296: H1466-H1483.
50. Molkentin JD. The zinc finger-containing transcription factors GATA-4, -5, and -6: ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 2000; 275: 38949-38952.
51. Frampton AE, Castellano L, Colombo T, Giovannetti E, Krell J, Jacob J et al. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. Gastroenterology 2014; 146: 268-277 e18.
52. Chen Y, Lewis W, Diwan A, Cheng EHY, Matkovich SJ, Dorn GW. Dual autonomous mitochondrial cell death pathways are activated by Nix/BNip3L and induce cardiomyopathy. Proc Natl Acad Sci 2010; 107: 9035-9042.
53. Merlet N, Piriou N, Rozec B, Grabherr A, Lauzier B, Trochu J-N et al. Increased beta2- adrenoceptors in doxorubicin-induced cardiomyopathy in rat. PLoS One 2013; 8: e64711.
54. Fajardo G, Zhao M, Urashima T, Farahani S, Hu D-Q, Reddy S et al. Deletion of the β2- adrenergic receptor prevents the development of cardiomyopathy in mice. J Mol Cell Cardiol 2013; 63: 155-164.
55. Pan W, Zhong Y, Cheng C, Liu B,Wang L, Li A et al. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS One 2013; 8: e53950.
56. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007; 31: 367-373.
57. Zhu W-Z, Wang S-Q, Chakir K, Yang D, Zhang T, Brown JH et al. Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A, independent activation of Ca2+/calmodulin kinase II. J Clin Invest 2003; 111: 617-625.
58. van Rooij E, Marshall WS, Olson EN. Toward MicroRNA-Based Therapeutics for Heart Disease: The Sense in Antisense. Circ Res 2008; 103: 919-928.
59. Zhu W-Z, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao R-P. Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA 2001; 98: 1607-1612.
60. Green PS, Leeuwenburgh C. Mitochondrial dysfunction is an early indicator of doxorubicininduced apoptosis. Biochim Biophys Acta 2002; 1588: 94-101.
61. Narula J, Pandey P, Arbustini E, Haider N, Narula N, Kolodgie FD et al. Apoptosis in heart failure: Release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci USA 1999; 96: 8144-8149.
62. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 2011; 29: 2635-2644.
63. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT,Meric-Bernstam F et al. Beta-Blocker use is associated with improved relapse-free survival in patients with triplenegative breast cancer. J Clin Oncol 2011; 29: 2645-2652.
64. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A et al. Behavioral stress accelerates prostate cancer development in mice. J Clin Invest 2013; 123: 874-886.
65. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70: 7042-7052.
66. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS et al. The norepinephrinedriven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β-blockers. Int J Cancer 2006; 118: 2744-2749.
67. Kao CJ, Martiniez A, Shi XB, Yang J, Evans CP, Dobi A et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 2013.
68. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013; 4: 1393.
69. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29: 4194-4204.
70. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z et al. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 2013; 33: 3119-3128.